Dexcom G6 CGM Receives CMS Approval & Will Be Available to Medicare Beneficiaries in Early 2019

image003 (1).jpg

More great news has been announced about CGM! The Dexcom G6 continuous glucose monitor (CGM) will be covered for Medicare beneficiaries, starting in early 2019. CGMs are DME items that provide critical information on blood glucose levels to help patients with diabetes better manage their disease. Coverage for therapeutic CGM includes certain beneficiaries who have either Type 1 or Type 2 diabetes and intensively manage their insulin.

The Dexcom G6 CGM shines because of the following advantages:

  1. Zero fingersticks

  2. Acetaminophen blocking to maintain accuracy while taking Tylenol

  3. Smartphone app that allows data to be shared with family members, providers, and other members of a patient's care team

  4. Super easy application device

  5. Very small and discreet sensor

  6. Integration with the tSlim:X2 insulin pump from Tandem Diabetes, which is also covered by Medicare

Healthy Living will be able to provide the G6 to Medicare members – stay tuned for updates on this exciting news! Read the press release directly from Dexcom.